Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 18, Issue 10, 2012, Pages 1855-1858

  Sultan, Keith ^a   Korelitz, Burton I ^b   Present, Daniel ^c   Katz, Seymour ^a   Sunday, Suzanne ^d   Shapira, Iuliana ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b LENOX HILL HOSPITAL   (United States)

^c MOUNT SINAI HOSPITAL   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

6 mercaptopurine; azathioprine; lymphoma; prognosis

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE;

ADOLESCENT; ADULT; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CROHN DISEASE; DATA BASE; ENTERITIS; ETHNICITY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GENDER; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; ULCERATIVE COLITIS; WALDENSTROEM MACROGLOBULINEMIA;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84866379750     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22866     Document Type: Article

References (20)

1. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980; 302: 981-987. (Pubitemid 10125406)
2. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J. Med; 362: 1383-1395.
3. Brooke BN, Hoffmann DC, Swarbrick ET,. Azathioprine for Crohn's disease. Lancet. 1969; 2: 612-614.
4. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000: CD000545.
5. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001; 121: 1080-1087. (Pubitemid 33022087)
6. Pedersen N, Duricova D, Elkjaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010; 105: 1480-1387.
7. Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther. 2004; 19: 287-293. (Pubitemid 38253503)
8. Ekbom A, Helmick C, Zack M, et al. Extracolonic malignancies in inflammatory bowel disease. Cancer. 1991; 67: 2015-2019.
9. Persson PG, Karlen P, Bernell O, et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology. 1994; 107: 1675-1679. (Pubitemid 24357620)
10. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005; 54: 617-622. (Pubitemid 40559243)
11. Armstrong RG, West J, Card TR,. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol. 2010; 105: 1604-1609.
12. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54: 1121-1125. (Pubitemid 41025906)
13. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009; 374: 1617-1625.
14. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002; 122: 72-77. (Pubitemid 34049196)
15. Korelitz BI, Mirsky FJ, Fleisher MR, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol. 1999; 94: 3248-3253.
16. Fraser AG, Orchard TR, Robinson EM, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002; 16: 1225-1232.
17. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000; 47: 514-519.
18. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010; 9: 36-41 e1.
19. Siegel CA, Marden SM, Persing, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009; 7: 874-881.
20. Lewis JD, Schwartz JS, Lichtenstein GR,. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000; 118: 1018-1024. (Pubitemid 30346977)